English

Caribou Biosciences, Inc.

EDGAR

CRBU Quarterly report (10-Q) · filed 2026-08-13

Annual consolidated revenue for 2025: about USD 11.16M, using the latest reported figures. The previous period, 2024, was about USD 9.994M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

1.5 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 1499000 USD Source

Operating margin

-1,690.39%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -25339000 USD Source
Revenue: 1499000 USD Source

Operating cash flow

-22.8 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -49800000 USD Source
Operating Cash Flow: -27000000 USD Source

Free cash flow

-22.8 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -49800000 USD Source
Operating Cash Flow: -27000000 USD Source
Capital Expenditure: 73000 USD Source
Capital Expenditure: 72000 USD Source

Cash and cash equivalents: 26.2 million USD 2026-06-30 Source
Exact value

26194000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 106 million shares 2026-06-30 Source
Exact value

105995653 shares

Reported share-count change

13.82% · 12.9 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

93123239 shares · 2025-06-30· Source
105995653 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

10 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 2198000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 11159000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 7218000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 2397000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 1499000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-103 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -27548000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -148125000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -121637000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -25085000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -24282000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-95.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -90200000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -64983000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -111000000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -90200000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -27000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -49800000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -27000000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-13.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+11.7%

Prior period

USD 9.99 million

2024-01-01 – 2024-12-31
Current period

USD 11.16 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

11159000 − 9994000 = 1165000 USD

9994000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
11159000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Caribou Biosciences, Inc. · 2025-12-31 Caribou Biosciences, Inc. (edgar:1619856) Year-over-year change in Revenue: 1165000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 11159000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1847200 Filing: 000161985626000008 Input fundies:Revenue: 9994000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1848174 Filing: 000161985626000008
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 980,000

Prior period

−USD 149.11 million

2024-01-01 – 2024-12-31
Current period

−USD 148.13 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-148125000 − -149105000 = 980000 USD

-149105000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-148125000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Caribou Biosciences, Inc. · 2025-12-31 Caribou Biosciences, Inc. (edgar:1619856) Year-over-year change in Net income: 980000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -148125000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#2158909 Filing: 000161985626000008 Input fundies:NetIncome: -149105000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#2159683 Filing: 000161985626000008
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 27.2 million

Prior period

−USD 138.2 million

2024-01-01 – 2024-12-31
Current period

−USD 111 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-111000000 − -138200000 = 27200000 USD

-138200000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-111000000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Caribou Biosciences, Inc. · 2025-12-31 Caribou Biosciences, Inc. (edgar:1619856) Year-over-year change in Operating cash flow: 27200000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -111000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1605065 Filing: 000161985626000008 Input fundies:OperatingCashFlow: -138200000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1566439 Filing: 000161985626000008
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-72.2%

Prior period

USD 4.88 million

2024-01-01 – 2024-12-31
Current period

USD 1.36 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1359000 − 4880000 = -3521000 USD

4880000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1359000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Caribou Biosciences, Inc. · 2025-12-31 Caribou Biosciences, Inc. (edgar:1619856) Year-over-year change in Capital expenditure: -3521000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1359000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1570664 Filing: 000161985626000008 Input fundies:CapitalExpenditure: 4880000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1571253 Filing: 000161985626000008
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 11.16 million 100% of revenue
Operating costs Derived USD 159.5 million 1,429% of revenue
Operating income −USD 148.34 million −1,329% of revenue
Tax, interest and other Derived −USD 219,000 −2% of revenue
Net income −USD 148.13 million −1,327% of revenue

Cash

Operating cash flow −USD 111 million −995% of revenue
Capital expenditure USD 1.36 million 12% of revenue
Free cash flow Derived −USD 112.36 million −1,007% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 693% of revenue.
2020 Operating loss: operating costs were 392% of revenue.
2021 Operating loss: operating costs were 798% of revenue.
2022 Operating loss: operating costs were 868% of revenue.
2023 Operating loss: operating costs were 437% of revenue.
2024 Operating loss: operating costs were 1,767% of revenue.
2025 Operating loss: operating costs were 1,429% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	5788000	40093000 Derived	-34305000	-10874000 Derived	-23431000	-32890000 Derived	Source 2019-01-01 – 2019-12-31: 5788000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -34305000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -23431000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -32006000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 884000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	12361000	48485000 Derived	-36124000	-1816000 Derived	-34308000	-33532000 Derived	Source 2020-01-01 – 2020-12-31: 12361000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -36124000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -34308000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -33215000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 317000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	9598000	76577000 Derived	-66979000	-56000 Derived	-66923000	-34640000 Derived	Source 2021-01-01 – 2021-12-31: 9598000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -66979000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -66923000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -32519000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 2121000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	13851000	120250000 Derived	-106399000	-6978000 Derived	-99421000	-97420000 Derived	Source 2022-01-01 – 2022-12-31: 13851000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -106399000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -99421000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -90966000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 6454000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	34477000	150536000 Derived	-116059000	-13989000 Derived	-102070000	-104904000 Derived	Source 2023-01-01 – 2023-12-31: 34477000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -116059000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -102070000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -93291000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 11613000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	9994000	176610000 Derived	-166616000	-17511000 Derived	-149105000	-143080000 Derived	Source 2024-01-01 – 2024-12-31: 9994000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -166616000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -149105000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -138200000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 4880000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	11159000	159503000 Derived	-148344000	-219000 Derived	-148125000	-112359000 Derived	Source 2025-01-01 – 2025-12-31: 11159000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -148344000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -148125000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -111000000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 1359000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 11.2M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	5788000	Revenue: 5788000 Open source
20202020-12-31	Revenue	12361000	Revenue: 12361000 Open source
20212021-12-31	Revenue	9598000	Revenue: 9598000 Open source
20222022-12-31	Revenue	13851000	Revenue: 13851000 Open source
20232023-12-31	Revenue	34477000	Revenue: 34477000 Open source
20242024-12-31	Revenue	9994000	Revenue: 9994000 Open source
20252025-12-31	Revenue	11159000	Revenue: 11159000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

11.7% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 5788000 Open source
20202020-12-31	Year over year	113.6%	Revenue: 12361000 Open source Revenue: 5788000 Open source
20212021-12-31	Year over year	-22.4%	Revenue: 9598000 Open source Revenue: 12361000 Open source
20222022-12-31	Year over year	44.3%	Revenue: 13851000 Open source Revenue: 9598000 Open source
20232023-12-31	Year over year	148.9%	Revenue: 34477000 Open source Revenue: 13851000 Open source
20242024-12-31	Year over year	-71%	Revenue: 9994000 Open source Revenue: 34477000 Open source
20252025-12-31	Year over year	11.7%	Revenue: 11159000 Open source Revenue: 9994000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,329.4% 2025

Net margin -1,327.4% 2025

Free cash flow margin -1,006.9% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-592.7%	Operating Income: -34305000 Open source Revenue: 5788000 Open source
20202020-12-31	Operating margin	-292.2%	Operating Income: -36124000 Open source Revenue: 12361000 Open source
20212021-12-31	Operating margin	-697.8%	Operating Income: -66979000 Open source Revenue: 9598000 Open source
20222022-12-31	Operating margin	-768.2%	Operating Income: -106399000 Open source Revenue: 13851000 Open source
20232023-12-31	Operating margin	-336.6%	Operating Income: -116059000 Open source Revenue: 34477000 Open source
20242024-12-31	Operating margin	-1,667.2%	Operating Income: -166616000 Open source Revenue: 9994000 Open source
20252025-12-31	Operating margin	-1,329.4%	Operating Income: -148344000 Open source Revenue: 11159000 Open source
20192019-12-31	Net margin	-404.8%	Net Income: -23431000 Open source Revenue: 5788000 Open source
20202020-12-31	Net margin	-277.6%	Net Income: -34308000 Open source Revenue: 12361000 Open source
20212021-12-31	Net margin	-697.3%	Net Income: -66923000 Open source Revenue: 9598000 Open source
20222022-12-31	Net margin	-717.8%	Net Income: -99421000 Open source Revenue: 13851000 Open source
20232023-12-31	Net margin	-296.1%	Net Income: -102070000 Open source Revenue: 34477000 Open source
20242024-12-31	Net margin	-1,491.9%	Net Income: -149105000 Open source Revenue: 9994000 Open source
20252025-12-31	Net margin	-1,327.4%	Net Income: -148125000 Open source Revenue: 11159000 Open source
20192019-12-31	Free cash flow margin	-568.2%	Revenue: 5788000 Open source Operating Cash Flow: -32006000 Open source Capital Expenditure: 884000 Open source
20202020-12-31	Free cash flow margin	-271.3%	Revenue: 12361000 Open source Operating Cash Flow: -33215000 Open source Capital Expenditure: 317000 Open source
20212021-12-31	Free cash flow margin	-360.9%	Revenue: 9598000 Open source Operating Cash Flow: -32519000 Open source Capital Expenditure: 2121000 Open source
20222022-12-31	Free cash flow margin	-703.3%	Revenue: 13851000 Open source Operating Cash Flow: -90966000 Open source Capital Expenditure: 6454000 Open source
20232023-12-31	Free cash flow margin	-304.3%	Revenue: 34477000 Open source Operating Cash Flow: -93291000 Open source Capital Expenditure: 11613000 Open source
20242024-12-31	Free cash flow margin	-1,431.7%	Revenue: 9994000 Open source Operating Cash Flow: -138200000 Open source Capital Expenditure: 4880000 Open source
20252025-12-31	Free cash flow margin	-1,006.9%	Revenue: 11159000 Open source Operating Cash Flow: -111000000 Open source Capital Expenditure: 1359000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -111M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-32006000	Operating Cash Flow: -32006000 Open source
20202020-12-31	Operating cash flow	-33215000	Operating Cash Flow: -33215000 Open source
20212021-12-31	Operating cash flow	-32519000	Operating Cash Flow: -32519000 Open source
20222022-12-31	Operating cash flow	-90966000	Operating Cash Flow: -90966000 Open source
20232023-12-31	Operating cash flow	-93291000	Operating Cash Flow: -93291000 Open source
20242024-12-31	Operating cash flow	-138200000	Operating Cash Flow: -138200000 Open source
20252025-12-31	Operating cash flow	-111000000	Operating Cash Flow: -111000000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -112.4M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-32890000	Operating Cash Flow: -32006000 Open source Capital Expenditure: 884000 Open source
20202020-12-31	Free cash flow	-33532000	Operating Cash Flow: -33215000 Open source Capital Expenditure: 317000 Open source
20212021-12-31	Free cash flow	-34640000	Operating Cash Flow: -32519000 Open source Capital Expenditure: 2121000 Open source
20222022-12-31	Free cash flow	-97420000	Operating Cash Flow: -90966000 Open source Capital Expenditure: 6454000 Open source
20232023-12-31	Free cash flow	-104904000	Operating Cash Flow: -93291000 Open source Capital Expenditure: 11613000 Open source
20242024-12-31	Free cash flow	-143080000	Operating Cash Flow: -138200000 Open source Capital Expenditure: 4880000 Open source
20252025-12-31	Free cash flow	-112359000	Operating Cash Flow: -111000000 Open source Capital Expenditure: 1359000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

30.3% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2019-12-31	Liabilities / assets	Not reported	No source recorded
20202020-12-31	Liabilities / assets	50.4%	Total Liabilities: 18160000 Open source Total Assets: 36046000 Open source
20212021-12-31	Liabilities / assets	12.3%	Total Liabilities: 54531000 Open source Total Assets: 442356000 Open source
20222022-12-31	Liabilities / assets	19.5%	Total Liabilities: 72894000 Open source Total Assets: 373765000 Open source
20232023-12-31	Liabilities / assets	14.8%	Total Liabilities: 63808000 Open source Total Assets: 432209000 Open source
20242024-12-31	Liabilities / assets	19.3%	Total Liabilities: 60362000 Open source Total Assets: 313313000 Open source
20252025-12-31	Liabilities / assets	30.3%	Total Liabilities: 53192000 Open source Total Assets: 175367000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.71× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2019-12-31	Current assets / current liabilities	Not reported	No source recorded
20202020-12-31	Current assets / current liabilities	1.96×	Current Assets: 24306000 Open source Current Liabilities: 12389000 Open source
20212021-12-31	Current assets / current liabilities	15.15×	Current Assets: 391192000 Open source Current Liabilities: 25829000 Open source
20222022-12-31	Current assets / current liabilities	9.25×	Current Assets: 260248000 Open source Current Liabilities: 28128000 Open source
20232023-12-31	Current assets / current liabilities	11.97×	Current Assets: 338841000 Open source Current Liabilities: 28302000 Open source
20242024-12-31	Current assets / current liabilities	7.16×	Current Assets: 219377000 Open source Current Liabilities: 30651000 Open source
20252025-12-31	Current assets / current liabilities	5.71×	Current Assets: 145232000 Open source Current Liabilities: 25414000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 23.43 million Exact value Exact value: -23431000 USD 2019-01-01 – 2019-12-31: -23431000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Caribou Biosciences, Inc. · 2019-12-31 Caribou Biosciences, Inc. (edgar:1619856) Net Income: -23431000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -23431000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000095017022004233/crbu-20211231.htm#5138944 Filing: 000095017022004233 The citation records this snapshot. The page link may show a newer release later.	−USD 32.01 million Exact value Exact value: -32006000 USD 2019-01-01 – 2019-12-31: -32006000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Caribou Biosciences, Inc. · 2019-12-31 Caribou Biosciences, Inc. (edgar:1619856) Operating Cash Flow: -32006000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32006000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000095017022004233/crbu-20211231.htm#3503661 Filing: 000095017022004233 The citation records this snapshot. The page link may show a newer release later.	USD 884,000 Exact value Exact value: 884000 USD 2019-01-01 – 2019-12-31: 884000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Caribou Biosciences, Inc. · 2019-12-31 Caribou Biosciences, Inc. (edgar:1619856) Capital Expenditure: 884000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 884000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000095017022004233/crbu-20211231.htm#3518402 Filing: 000095017022004233 The citation records this snapshot. The page link may show a newer release later.	−USD 32.89 million Calculation and evidence -32006000 − 884000 USD Exact free cash flow: -32890000 USD 2019-01-01 – 2019-12-31: -32006000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 884000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Caribou Biosciences, Inc. · 2019-12-31 Caribou Biosciences, Inc. (edgar:1619856) Free cash flow: -32890000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32006000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000095017022004233/crbu-20211231.htm#3503661 Filing: 000095017022004233 Input fundies:CapitalExpenditure: 884000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000095017022004233/crbu-20211231.htm#3518402 Filing: 000095017022004233 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 34.31 million Exact value Exact value: -34308000 USD 2020-01-01 – 2020-12-31: -34308000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Caribou Biosciences, Inc. · 2020-12-31 Caribou Biosciences, Inc. (edgar:1619856) Net Income: -34308000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -34308000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000095017022004233/crbu-20211231.htm#5136750 Filing: 000095017022004233 The citation records this snapshot. The page link may show a newer release later.	−USD 33.22 million Exact value Exact value: -33215000 USD 2020-01-01 – 2020-12-31: -33215000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Caribou Biosciences, Inc. · 2020-12-31 Caribou Biosciences, Inc. (edgar:1619856) Operating Cash Flow: -33215000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33215000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000095017022004233/crbu-20211231.htm#3501889 Filing: 000095017022004233 The citation records this snapshot. The page link may show a newer release later.	USD 317,000 Exact value Exact value: 317000 USD 2020-01-01 – 2020-12-31: 317000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Caribou Biosciences, Inc. · 2020-12-31 Caribou Biosciences, Inc. (edgar:1619856) Capital Expenditure: 317000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 317000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000095017022004233/crbu-20211231.htm#3516759 Filing: 000095017022004233 The citation records this snapshot. The page link may show a newer release later.	−USD 33.53 million Calculation and evidence -33215000 − 317000 USD Exact free cash flow: -33532000 USD 2020-01-01 – 2020-12-31: -33215000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 317000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Caribou Biosciences, Inc. · 2020-12-31 Caribou Biosciences, Inc. (edgar:1619856) Free cash flow: -33532000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33215000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000095017022004233/crbu-20211231.htm#3501889 Filing: 000095017022004233 Input fundies:CapitalExpenditure: 317000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000095017022004233/crbu-20211231.htm#3516759 Filing: 000095017022004233 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 66.92 million Exact value Exact value: -66923000 USD 2021-01-01 – 2021-12-31: -66923000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Caribou Biosciences, Inc. · 2021-12-31 Caribou Biosciences, Inc. (edgar:1619856) Net Income: -66923000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -66923000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000037/crbu-20221231.htm#2767957 Filing: 000161985623000037 The citation records this snapshot. The page link may show a newer release later.	−USD 32.52 million Exact value Exact value: -32519000 USD 2021-01-01 – 2021-12-31: -32519000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Caribou Biosciences, Inc. · 2021-12-31 Caribou Biosciences, Inc. (edgar:1619856) Operating Cash Flow: -32519000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32519000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000037/crbu-20221231.htm#1847898 Filing: 000161985623000037 The citation records this snapshot. The page link may show a newer release later.	USD 2.12 million Exact value Exact value: 2121000 USD 2021-01-01 – 2021-12-31: 2121000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Caribou Biosciences, Inc. · 2021-12-31 Caribou Biosciences, Inc. (edgar:1619856) Capital Expenditure: 2121000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2121000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000037/crbu-20221231.htm#1855101 Filing: 000161985623000037 The citation records this snapshot. The page link may show a newer release later.	−USD 34.64 million Calculation and evidence -32519000 − 2121000 USD Exact free cash flow: -34640000 USD 2021-01-01 – 2021-12-31: -32519000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 2121000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Caribou Biosciences, Inc. · 2021-12-31 Caribou Biosciences, Inc. (edgar:1619856) Free cash flow: -34640000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32519000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000037/crbu-20221231.htm#1847898 Filing: 000161985623000037 Input fundies:CapitalExpenditure: 2121000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000037/crbu-20221231.htm#1855101 Filing: 000161985623000037 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 99.42 million Exact value Exact value: -99421000 USD 2022-01-01 – 2022-12-31: -99421000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Caribou Biosciences, Inc. · 2022-12-31 Caribou Biosciences, Inc. (edgar:1619856) Net Income: -99421000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -99421000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000013/crbu-20231231.htm#2277713 Filing: 000161985624000013 The citation records this snapshot. The page link may show a newer release later.	−USD 90.97 million Exact value Exact value: -90966000 USD 2022-01-01 – 2022-12-31: -90966000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Caribou Biosciences, Inc. · 2022-12-31 Caribou Biosciences, Inc. (edgar:1619856) Operating Cash Flow: -90966000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -90966000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000013/crbu-20231231.htm#1639681 Filing: 000161985624000013 The citation records this snapshot. The page link may show a newer release later.	USD 6.45 million Exact value Exact value: 6454000 USD 2022-01-01 – 2022-12-31: 6454000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Caribou Biosciences, Inc. · 2022-12-31 Caribou Biosciences, Inc. (edgar:1619856) Capital Expenditure: 6454000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6454000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000013/crbu-20231231.htm#1644527 Filing: 000161985624000013 The citation records this snapshot. The page link may show a newer release later.	−USD 97.42 million Calculation and evidence -90966000 − 6454000 USD Exact free cash flow: -97420000 USD 2022-01-01 – 2022-12-31: -90966000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 6454000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Caribou Biosciences, Inc. · 2022-12-31 Caribou Biosciences, Inc. (edgar:1619856) Free cash flow: -97420000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -90966000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000013/crbu-20231231.htm#1639681 Filing: 000161985624000013 Input fundies:CapitalExpenditure: 6454000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000013/crbu-20231231.htm#1644527 Filing: 000161985624000013 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 102.07 million Exact value Exact value: -102070000 USD 2023-01-01 – 2023-12-31: -102070000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Caribou Biosciences, Inc. · 2023-12-31 Caribou Biosciences, Inc. (edgar:1619856) Net Income: -102070000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -102070000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000015/crbu-20241231.htm#2305443 Filing: 000161985625000015 The citation records this snapshot. The page link may show a newer release later.	−USD 93.29 million Exact value Exact value: -93291000 USD 2023-01-01 – 2023-12-31: -93291000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Caribou Biosciences, Inc. · 2023-12-31 Caribou Biosciences, Inc. (edgar:1619856) Operating Cash Flow: -93291000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -93291000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000015/crbu-20241231.htm#1657098 Filing: 000161985625000015 The citation records this snapshot. The page link may show a newer release later.	USD 11.61 million Exact value Exact value: 11613000 USD 2023-01-01 – 2023-12-31: 11613000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Caribou Biosciences, Inc. · 2023-12-31 Caribou Biosciences, Inc. (edgar:1619856) Capital Expenditure: 11613000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11613000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000015/crbu-20241231.htm#1661943 Filing: 000161985625000015 The citation records this snapshot. The page link may show a newer release later.	−USD 104.9 million Calculation and evidence -93291000 − 11613000 USD Exact free cash flow: -104904000 USD 2023-01-01 – 2023-12-31: -93291000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 11613000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Caribou Biosciences, Inc. · 2023-12-31 Caribou Biosciences, Inc. (edgar:1619856) Free cash flow: -104904000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -93291000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000015/crbu-20241231.htm#1657098 Filing: 000161985625000015 Input fundies:CapitalExpenditure: 11613000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000015/crbu-20241231.htm#1661943 Filing: 000161985625000015 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 149.11 million Exact value Exact value: -149105000 USD 2024-01-01 – 2024-12-31: -149105000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Caribou Biosciences, Inc. · 2024-12-31 Caribou Biosciences, Inc. (edgar:1619856) Net Income: -149105000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -149105000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#2159683 Filing: 000161985626000008 The citation records this snapshot. The page link may show a newer release later.	−USD 138.2 million Exact value Exact value: -138200000 USD 2024-01-01 – 2024-12-31: -138200000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Caribou Biosciences, Inc. · 2024-12-31 Caribou Biosciences, Inc. (edgar:1619856) Operating Cash Flow: -138200000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -138200000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1566439 Filing: 000161985626000008 The citation records this snapshot. The page link may show a newer release later.	USD 4.88 million Exact value Exact value: 4880000 USD 2024-01-01 – 2024-12-31: 4880000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Caribou Biosciences, Inc. · 2024-12-31 Caribou Biosciences, Inc. (edgar:1619856) Capital Expenditure: 4880000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4880000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1571253 Filing: 000161985626000008 The citation records this snapshot. The page link may show a newer release later.	−USD 143.08 million Calculation and evidence -138200000 − 4880000 USD Exact free cash flow: -143080000 USD 2024-01-01 – 2024-12-31: -138200000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 4880000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Caribou Biosciences, Inc. · 2024-12-31 Caribou Biosciences, Inc. (edgar:1619856) Free cash flow: -143080000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -138200000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1566439 Filing: 000161985626000008 Input fundies:CapitalExpenditure: 4880000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1571253 Filing: 000161985626000008 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 148.13 million Exact value Exact value: -148125000 USD 2025-01-01 – 2025-12-31: -148125000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Caribou Biosciences, Inc. · 2025-12-31 Caribou Biosciences, Inc. (edgar:1619856) Net Income: -148125000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -148125000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#2158909 Filing: 000161985626000008 The citation records this snapshot. The page link may show a newer release later.	−USD 111 million Exact value Exact value: -111000000 USD 2025-01-01 – 2025-12-31: -111000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Caribou Biosciences, Inc. · 2025-12-31 Caribou Biosciences, Inc. (edgar:1619856) Operating Cash Flow: -111000000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -111000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1605065 Filing: 000161985626000008 The citation records this snapshot. The page link may show a newer release later.	USD 1.36 million Exact value Exact value: 1359000 USD 2025-01-01 – 2025-12-31: 1359000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Caribou Biosciences, Inc. · 2025-12-31 Caribou Biosciences, Inc. (edgar:1619856) Capital Expenditure: 1359000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1359000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1570664 Filing: 000161985626000008 The citation records this snapshot. The page link may show a newer release later.	−USD 112.36 million Calculation and evidence -111000000 − 1359000 USD Exact free cash flow: -112359000 USD 2025-01-01 – 2025-12-31: -111000000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 1359000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Caribou Biosciences, Inc. · 2025-12-31 Caribou Biosciences, Inc. (edgar:1619856) Free cash flow: -112359000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T21:35:17Z Snapshot: 2526da2ff312836de29291e8afe69f90ea19802a2fe0f6afe57499c21db04e42 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1619856?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -111000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1605065 Filing: 000161985626000008 Input fundies:CapitalExpenditure: 1359000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm#1570664 Filing: 000161985626000008 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

31 filings · 1,795 latest values · 1,795 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001619856, 1619856, CRBU, edgar:1619856

Also known as Caribou Biosciences, Inc.

Caribou Biosciences, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation